Two Massive Commercial Flops May Send Chilling Effect Through Biotech Industry

New cholesterol drugs that were expected to make billions failed to live up to their potential. And the disappointing sales has the new sector - which relies on the idea that the risky, expensive process of developing new drugs can one day pay off big - on edge. Meanwhile, the market is in flux after a dour earnings report from one of the largest pharmaceutical distributors in the U.S.